Boomerang: Revolutionizing At-home Medical Testing
Positioned to become a leader in the fast-growing billion-dollar digital health market
Covid-19 changed everything.
Although we are on the “other side” of things in many ways, the pandemic ushered in a New Normal that’s put personal health and wellness in the spotlight.
People are more familiar than ever with medical testing and have a burning desire to know more about themselves.
Today’s featured company has recognized this trend as an opportunity to reinvent healthcare and has positioned itself to become a leader in the fast-growing billion-dollar digital health market: Boomerang, a Lotus Bio-Technology Development company.
Summary
- The New Normal: An Opportunity
- The Boomerang Difference: More than Results
- Scalability: Empowering a Global Audience
- Bottom Line
The New Normal: An Opportunity
Only a few years ago, unless they were employed in the medical field, there was little reason for anyone to know what PCR or antigen tests were.
Now, both have become a part of the everyday vernacular. It’s even common knowledge that the former is more effective than the latter.
The public is hyper-aware.
The reason should come as no surprise: Covid changed everything.
Now more than ever people have a desire to not only seek out knowledge pertaining to their personal health but to take proactive measures towards improving it.
To be sure, this trend has been in place for some time and has been accelerating with the rise of technology, but the global pandemic served as a massive catalyst that’s pulled forward the timeline for healthcare innovation.
We’ve seen this play out with the recent explosion of growth in health and wellness products ranging from fitness apps to fertility trackers. Consumers are hungry to learn more about themselves and their health.
It’s also made constant testing a part of the New Normal. This is being reflected in booming demand for at-home testing where the market size is expected to surpass $8 billion by 2027.
At-home testing has become ingrained in the New Normal because it’s a quick and easy way to gain personal insights into your health—with the test results.
But for current solutions (like Everlywell which was recently valued at $2.9 billion), this is where the experience ends—with the test results.
That’s a problem. Or rather…an opportunity.
The Boomerang Difference: More than Results
Boomerang is a medical testing company that leverages state-of-the-art at-home diagnostic testing and strategic partnerships to offer customizable wellness plans so that results are not the end of the road.
Everyone is different. Their journey to a healthier lifestyle should be different too, but self-care starts with self-discovery.
Boomerang serves as a launching pad toward that lifestyle at the point of results by laying out a tailored path and equipping people with the tools they need to conquer it.
Testing at home is made easy with a variety of user-friendly kits for quick saliva, urine, and blood collection that is virtually painless thanks to a partnership with state-of-the-art collection device Tasso.
Kits support women’s and men’s health, dietary health, sexual health, perimenopause, fertility, testosterone, STDs, food sensitivity, food sensitivity deluxe, indoor & outdoor allergy, vitamin D, heart health, sleep & stress, UTI, thyroid, and—of course—Covid-19 RT-PCR tests and rapid antigen tests.
After mailing test kits back to the labs—which we’ll get to—using a prepaid label, users can immediately create an account and access Boomerang’s community, marking the beginning—not the end—of their journey to wellness.
Within this community lies everything they’ll need to put their results to action on that journey, like sessions with nutritionists, personal trainers, and life coaches, personalized meal plans and meal kits, workout clothes and equipment, supplements to offset deficiencies, discounted health and wellness products, and more.
As we’ve iterated, with Boomerang the tests are just the beginning. They’re presented in a comprehensive but easy-to-understand way so people can focus on putting them into action rather than deciphering what they mean.
And they’re fast.
Other “at-home testing brands” rely on 3rd party vendors for test kit analysis. These are nothing more than marketing companies that are outsourcing the science.
Boomerang, on the other hand, does no such thing: it owns its (CLIA-certified) labs, and all staff members are employees. This provides several advantages over the competition which include but are not limited to faster turnaround times, the accuracy of results, and the ability to better manage costs.
Scalability & Vision: Empowering a Global Audience
While the direct-to-consumer (D2C) model is easily accessible, Boomerang Business is focused on the rapid expansion of digital health into a larger space with broader access to more people across the nation.
With brick-and-mortar facilities in California, Nevada, Arizona, and Florida, and agreements with over 75 labs across the US, Canada, and Europe, Boomerang is positioned to scale to empower a global audience.
Boomerang’s employer-based home testing solution is the next phase of the Telehealth boom.
Or rather, it already is: school districts, film crews, and large corporations alike trust its test kits and services on a weekly basis in this New Normal.
Boomerang helps these businesses and organizations by providing comprehensive, end-to-end solutions to manage large-quantity testing for all staff sizes.
Businesses you may or may not have heard of, like Netflix, Amazon Prime Video, AutoZone, CBS, Discovery Channel, HBO Max, and so on.
It seamlessly handles onboarding to integrate employees into one easily managed system and delivers individual and aggregated results after each session of testing.
This lets employees and HR professionals go beyond mere health reimbursements—it empowers them to make healthier choices based on personalized medical results.
Within this New Normal, Boomerang’s vision for the future is to empower entire towns and cities towards healthier lifestyles for residents, leading to a larger community.
A larger, more engaged community of like-minded people ready to pursue personal health & wellness with an unparalleled desire.
This is a community that health & wellness brands would absolutely kill to be able to tap into directly, and that gives Boomerang (who controls the inroads to it) enormous value.
Boomerang’s go-to-market strategy is to continue to build this two-sided network that serves (and adds value to) the entire health & wellness ecosystem.
Bottom Line
Covid changed everything.
It’s heightened public awareness.
It’s made constant testing the New Normal.
It’s sparked a demand in people seeking ownership over their health and accelerated people’s familiarity with at-home medical testing.
With its focus on building a community of and for these people that begins at the point of results, Boomerang is uniquely positioned to become a leader within the fast-growing billion-dollar digital health market.
The demand for peace of mind has never been higher.
Boomerang is delivering it, and then some!
Click here to find out more about this opportunity.
Gritcapital.substack.com (“Grit”) is a website owned and operated by Substack. Grit is paid fees by the companies that make investment offerings on this website. Be aware that payment of these fees may put Grit in a conflict of interest with the investor. By accessing this website or any page thereof, you agree to be bound by the Terms of Use and Privacy Policy, in effect at the time you access this website or any page thereof. The Terms of Use and Privacy Policy may be amended from time to time. Nothing on this website shall constitute an offer to sell, or a solicitation of an offer to buy or subscribe for, any securities to any person in any jurisdiction where such an offer or solicitation is against the law or to anyone to whom it is unlawful to make such offer or solicitation. Grit is not an underwriter, broker-dealer, Title III crowdfunding portal or a valuation service and does not engage in any activities requiring any such registration. Grit does not provide advice on investments or structure transactions. Offerings made under Regulation A under the U.S. Securities Act of 1933, as amended (the “Securities Act”) are available to U.S. investors who are “accredited investors” as defined by Rule 501 of Regulation D under the Securities Act well as non-accredited investors, who are subject to certain investment limitations as set forth in Regulation A under the Securities Act. In order to invest in Regulation A offerings, investors may be asked to fill out a certification and provide necessary documentation as proof of your income and/or net worth to verify that you are qualified to invest in offerings posted on this website. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. Grit does not verify the adequacy, accuracy or completeness of any information. Neither Grit nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, valuations of securities or completeness of any information on this site or the use of information on this site. Neither Grit nor any of its directors, officers, employees, representatives, affiliates or agents shall have any liability whatsoever arising from any error or incompleteness of fact, or lack of care in the preparation of, any of the materials posted on this website. Investing in securities, especially those issued by start-up companies, involves substantial risk. investors should be able to bear the loss of their entire investment and should make their own determination of whether or not to make any investment based on their own independent evaluation and analysis.
The information contained on this website has been prepared by the paid advertiser Boomerang, a Lotus Bio-Technology development company. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser. Boomerang, a Lotus Bio-Technology development company has paid $87,480 to have this content (in addition to other content on other social media sites) created and published. GetVersed is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
The information contained on this website has been prepared by the paid advertiser. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser.
Grit Capital Corporation is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN. INVESTORS SHOULD OBTAIN INDIVIDUAL FINANCIAL ADVICE BASED ON THEIR OWN CIRCUMSTANCES BEFORE MAKING AN INVESTMENT DECISION.
No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.
Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.
The publisher, its affiliates, and clients of the publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.
Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.